Pharmadrug (TSE:PHRX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PharmaDrug has commenced a clinical study for PD-001, a patented enteric-coated cepharanthine, aimed at treating viral infections. The study will assess bioavailability and pharmacokinetics in volunteers, with the goal to improve upon the drug’s traditionally low bioavailability. Positive results could lead to Phase 2 trials and attract potential pharmaceutical partners or investors.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
